VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Authors
Keywords
-
Journal
ANNALS OF MEDICINE
Volume 54, Issue 1, Pages 1089-1111
Publisher
Informa UK Limited
Online
2022-04-22
DOI
10.1080/07853890.2022.2064541
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Faricimab: an investigational agent targeting the Tie-2/Angiopoietin pathway and VEGF-A for the treatment of retinal diseases
- (2021) Massimo Nicolò et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Anti-VEGF Crunch Syndrome in Proliferative Diabetic Retinopathy: A Review
- (2021) Yiran Tan et al. SURVEY OF OPHTHALMOLOGY
- Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
- (2021) Raj K. Maturi et al. JAMA Ophthalmology
- Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study
- (2020) Jean-François Korobelnik et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE)
- (2020) Justus G. Garweg KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration
- (2020) Quan Dong Nguyen et al. OPHTHALMOLOGY
- Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy
- (2020) Maureen G. Maguire et al. JAMA Ophthalmology
- Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results
- (2020) John F. Payne et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- One-Year Effectiveness Study of Intravitreously Administered Conbercept® Monotherapy in Diabetic Macular Degeneration: A Systematic Review and Meta-Analysis
- (2020) Heping Wang et al. Diabetes Therapy
- Emerging drugs for the treatment of diabetic retinopathy
- (2020) Elio Striglia et al. EXPERT OPINION ON EMERGING DRUGS
- Anti-Vascular Endothelial Growth Factor Therapy as an Alternative or Adjunct to Pan-Retinal Photocoagulation in Treating Proliferative Diabetic Retinopathy: Meta-Analysis of Randomized Trials
- (2020) Shuang Gao et al. Frontiers in Pharmacology
- Intravitreal anti‐vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta‐analysis
- (2020) Matteo Fallico et al. ACTA OPHTHALMOLOGICA
- Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration
- (2020) Ramin Tadayoni et al. OPHTHALMOLOGICA
- Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study
- (2019) Xiaoxin Li et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
- (2019) Jayashree Sahni et al. OPHTHALMOLOGY
- Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes
- (2019) John F. Payne et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity
- (2019) Carl W. Baker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Brolucizimab—leading an era of structural revolution for long-term VEGF suppression
- (2019) Ashish Sharma et al. EYE
- Advances in the treatment of diabetic retinopathy
- (2019) Rishi P. Singh et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glia of the human retina
- (2019) Andreas Reichenbach et al. GLIA
- Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives
- (2018) Joana Mesquita et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)
- (2018) João Figueira et al. OPHTHALMOLOGY
- Mechanisms of macular edema: Beyond the surface
- (2018) Alejandra Daruich et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Rationale and Application of the Protocol S Anti–Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy
- (2018) Jennifer K. Sun et al. OPHTHALMOLOGY
- Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
- (2018) Jeffrey G. Gross et al. JAMA Ophthalmology
- Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 μg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)
- (2018) Michael A. Singer et al. Ophthalmic Surgery Lasers & Imaging Retina
- The efficacy and safety of aflibercept and conbercept in diabetic macular edema
- (2018) Siwei Cai et al. Drug Design Development and Therapy
- Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
- (2017) Sobha Sivaprasad et al. LANCET
- Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)
- (2017) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGICA
- Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema
- (2017) John F. Payne et al. OPHTHALMOLOGY
- Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab
- (2017) Susan B. Bressler et al. OPHTHALMOLOGY
- Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010
- (2016) Janet L. Leasher et al. DIABETES CARE
- Anti–Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease
- (2016) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Twenty-four–Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study
- (2016) Yasir J. Sepah et al. OPHTHALMOLOGY
- The progress in understanding and treatment of diabetic retinopathy
- (2016) Alan W. Stitt et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial
- (2016) Chelsea Fechter et al. Ophthalmic Surgery Lasers & Imaging Retina
- Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
- (2015) Christian Prünte et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Ziv-aflibercept in macular disease
- (2015) Ahmad M Mansour et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
- (2015) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2015) David M. Brown et al. OPHTHALMOLOGY
- The REVEAL Study
- (2015) Tatsuro Ishibashi et al. OPHTHALMOLOGY
- Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment
- (2015) Ian Pearce et al. OPHTHALMOLOGY
- ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY
- (2015) Matthew P. Simunovic et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
- (2015) Chiara B. M. Platania et al. Frontiers in Pharmacology
- Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study
- (2014) Eric H. Souied et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study)
- (2014) Oliver Comyn et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor A
- (2014) Jihong Yang et al. MOLECULAR PHARMACEUTICS
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2014) Jean-François Korobelnik et al. OPHTHALMOLOGY
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
- (2014) David S. Boyer et al. OPHTHALMOLOGY
- Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy
- (2013) JAMA Ophthalmology
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema
- (2012) Ranjan Rajendram et al. ARCHIVES OF OPHTHALMOLOGY
- Molecular Characteristics and Pathways of Avastin for the Treatment of Glioblastoma Multiforme
- (2012) Marko Spasic et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- Diabetic Retinopathy
- (2012) David A. Antonetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ranibizumab for Diabetic Macular Edema
- (2012) Quan Dong Nguyen et al. OPHTHALMOLOGY
- Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
- (2012) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema
- (2011) Peter A. Campochiaro et al. OPHTHALMOLOGY
- The RESTORE Study
- (2011) Paul Mitchell et al. OPHTHALMOLOGY
- Characterization of novel VEGF (vascular endothelial growth factor)-C splicing isoforms from mouse
- (2010) Zhen-Guo Wang et al. BIOCHEMICAL JOURNAL
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study
- (2010) P. Massin et al. DIABETES CARE
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
- (2010) Quan Dong Nguyen et al. OPHTHALMOLOGY
- A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)
- (2010) Michel Michaelides et al. OPHTHALMOLOGY
- VEGF-B
- (2010) Xuri Li et al. Cell Adhesion & Migration
- Snake Venom Vascular Endothelial Growth Factors (VEGF-Fs) Exclusively Vary Their Structures and Functions among Species
- (2009) Yasuo Yamazaki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice
- (2008) E S Rennel et al. BRITISH JOURNAL OF CANCER
- DARPins: A new generation of protein therapeutics
- (2008) Michael T. Stumpp et al. DRUG DISCOVERY TODAY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular endothelial growth factor in eye disease
- (2008) J.S. Penn et al. PROGRESS IN RETINAL AND EYE RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started